Commonwealth Coat of Arms

Criminal Code Regulations 2002

Statutory Rules No. 67, 2002 as amended

made under the

Criminal Code Act 1995

**Compilation start date:** 6 August 2014

**Includes amendments up to:** SLI No. 117, 2014

**About this compilation**

**This compilation**

This is a compilation of the *Criminal Code Regulations 2002* as in force on 6 August 2014. It includes any commenced amendment affecting the legislation to that date.

This compilation was prepared on 6 August 2014.

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of each amended provision.

**Uncommenced amendments**

The effect of uncommenced amendments is not reflected in the text of the compiled law but the text of the amendments is included in the endnotes.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Modifications**

If a provision of the compiled law is affected by a modification that is in force, details are included in the endnotes.

**Provisions ceasing to have effect**

If a provision of the compiled law has expired or otherwise ceased to have effect in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1 Name of Regulations 1

2 Commencement 1

3 Definition 1

Part 2—Security of the Commonwealth 2

4 Preventative detention orders—corresponding State preventative detention law 2

4H Terrorist organisations—Ansar al‑Islam 2

4J Terrorist organisations—Islamic Movement of Uzbekistan 3

4K Terrorist organisations—Jaish‑e‑Mohammad (JeM) 3

4L Terrorist organisations—Lashkar‑e Jhangvi (LeJ) 4

4Q Terrorist organisations—Hizballah’s External Security Organisation 4

4T Terrorist organisations—Palestinian Islamic Jihad 5

4U Terrorist organisations—Hamas’ Izz al‑Din al‑Qassam Brigades 5

4V Terrorist organisations—Lashkar‑e‑Tayyiba 5

4W Terrorist organisations—Kurdistan Workers Party (PKK) 7

4X Terrorist organisations—Al‑Shabaab 8

Part 3—Dangers to the community 9

Division 3.1—Cross‑border firearms trafficking 9

5 Cross‑border firearms trafficking 9

Division 3.2—Serious drugs and precursors 10

5A Controlled drugs 10

5B Controlled plants 10

5C Controlled precursors 11

5D Border controlled drugs 12

5E Border controlled plants 12

5F Border controlled precursors 13

Part 4—National infrastructure 15

6 Dangerous goods 15

Schedule 1—Corresponding State preventative detention law 16

Part 1—Laws of a State or Territory 16

Part 2—Particular provisions of a law of a State or Territory 17

Schedule 2—Cross‑border firearms trafficking 18

Schedule 3—Controlled drugs 19

Schedule 4—Border controlled drugs 30

Endnotes 39

Endnote 1—About the endnotes 39

Endnote 2—Abbreviation key 41

Endnote 3—Legislation history 42

Endnote 4—Amendment history 49

Endnote 5—Uncommenced amendments [none] 54

Endnote 6—Modifications [none] 54

Endnote 7—Misdescribed amendments [none] 54

Endnote 8—Miscellaneous [none] 54

Part 1—Preliminary

1 Name of Regulations

These Regulations are the *Criminal Code Regulations 2002*.

2 Commencement

These Regulations commence on gazettal.

3 Definition

In these Regulations:

***Code*** means the *Criminal Code*.

Part 2—Security of the Commonwealth

4 Preventative detention orders—corresponding State preventative detention law

(1) For the definition of ***corresponding State preventative detention law*** in subsection 100.1(1) of the Code, a law of a State or Territory that is set out in Part 1 of Schedule 1 is declared to correspond to Division 105 of the Code.

(2) For the definition of ***corresponding State preventative detention law*** in subsection 100.1(1) of the Code, particular provisions of a law of a State or Territory that are set out in Part 2 of Schedule 1 are declared to correspond to Division 105 of the Code.

4H Terrorist organisations—Ansar al‑Islam

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Ansar al‑Islam is specified.

(2) For subregulation (1), Ansar al‑Islam is also known by the following names:

(a) Ansar al‑Islam Army;

(b) Ansar al‑Sunna;

(c) Army of Ansar al‑Islam;

(d) Devotees of Islam;

(e) Followers of Islam in Kurdistan;

(f) Jaish Ansar al‑Islam;

(g) Jaish Ansar al‑Sunna;

(h) Jund al‑Islam;

(i) Kurdish Taliban;

(j) Kurdistan Supporters of Islam;

(k) Partisans of Islam;

(l) Protectors of Islam;

(m) Protectors of the Sunni Faith;

(n) Soldiers of God;

(o) Soldiers of Islam;

(p) Supporters of Islam in Kurdistan.

4J Terrorist organisations—Islamic Movement of Uzbekistan

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Islamic Movement of Uzbekistan is specified.

(2) For subregulation (1), Islamic Movement of Uzbekistan is also known by the following names:

(a) IMU;

(b) Islamic Movement of Turkestan;

(c) Islamic Party of Turkestan.

4K Terrorist organisations—Jaish‑e‑Mohammad (JeM)

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Jaish‑e‑Mohammad (JeM) is specified.

(2) For subregulation (1), Jaish‑e‑Mohammad (JeM) is also known by the following names:

(a) Army of Mohammed;

(b) Army of the Prophet;

(c) Jaish‑e‑Mohammed;

(d) Jaish‑e‑Muhammed;

(e) Jaish‑i‑Mohammed;

(f) Jaish‑i‑Mohammad;

(g) Jaish‑i‑Muhammad;

(h) Jaish‑i‑Muhammed;

(i) Jaish‑e‑Mohammad Mujahideen E‑Tanzeem;

(j) Jamaat ul‑Furqan (JuF);

(k) Jeish‑e‑Mahammed;

(l) Jesh‑e‑Mohammadi;

(m) Khudamul Islam;

(n) Khuddam ul‑Islam (KuI);

(o) Kuddam e Islami;

(p) Mohammed’s Army;

(q) National Movement for the Restoration of Pakistani Sovereignty and Army of the Prophet;

(r) Tehrik Ul‑Furqaan.

4L Terrorist organisations—Lashkar‑e Jhangvi (LeJ)

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Lashkar‑e Jhangvi (LeJ) is specified.

(2) For subregulation (1), Lashkar‑e Jhangvi (LeJ) is also known by the following names:

(a) Jhangvi Army;

(b) Lashkar e Jhangvi;

(c) Lashkar Jangvi;

(d) Lashkar Jhangvi;

(e) Lashkar‑e‑Jhangvie;

(f) Lashkar‑e‑Jhangwi;

(g) Lashkar‑e‑Jhanvi;

(h) Lashkar‑i‑Jangvi;

(i) Lashkar‑i‑Jhangvi;

(j) Lashkar‑i‑Jhangwi;

(k) Lashkare Jhangvi;

(l) Laskar e Jahangvi;

(m) Laskar‑e‑Jhangvi.

4Q Terrorist organisations—Hizballah’s External Security Organisation

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Hizballah’s External Security Organisation is specified.

(2) For subregulation (1), Hizballah’s External Security Organisation is also known by the following names:

(a) Foreign Action Unit;

(b) Hizballah ESO;

(c) Hizballah International;

(d) Islamic Jihad Organisation;

(e) Revolutionary Justice Organisation;

(f) Special Operations Branch.

4T Terrorist organisations—Palestinian Islamic Jihad

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Palestinian Islamic Jihad is specified.

(2) For subregulation (1), Palestinian Islamic Jihad is also known by the following names:

(a) al‑Quds Brigades;

(b) Harakat al‑Jihad al‑Islami fi Filistin;

(c) Islamic Jihad;

(d) Islamic Jihad Palestine;

(e) Islamic Jihad—Palestine Faction and Islamic Holy War;

(f) PIJ.

4U Terrorist organisations—Hamas’ Izz al‑Din al‑Qassam Brigades

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Hamas’ Izz al‑Din al‑Qassam Brigades is specified.

(2) For subregulation (1), Hamas’ Izz al‑Din al‑Qassam Brigades is also known by the following names:

(a) Ezzedeen Al‑Qassam Brigades;

(b) Izz al‑Din Al‑Qassem Brigades.

4V Terrorist organisations—Lashkar‑e‑Tayyiba

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Lashkar‑e‑Tayyiba is specified.

(2) For subregulation (1), Lashkar‑e‑Tayyiba is also known by the following names:

(a) al Mansooreen;

(b) al Mansoorian;

(c) Army of Medina;

(d) Army of the Pure;

(e) Army of the Pure and Righteous;

(f) Army of the Righteous;

(g) Falah‑e‑Insaniyat Foundation;

(h) Idara Khidmat‑e‑Khalq;

(i) Jama’at al‑Dawa;

(j) Jama’at‑i‑Dawat;

(k) Jamaati‑ud‑Dawa;

(l) Jamaat ud‑Daawa;

(m) Jama’at‑ud‑Da’awa;

(n) Jama’at‑ud‑Da’awah;

(o) Jamaat‑ud‑Dawa;

(p) Jama’at ul‑Da’awa;

(q) Jamaat‑ul‑Dawa;

(r) Jamaat ul‑Dawah;

(s) Jamaiat‑ud‑Dawa;

(t) JuD;

(u) JUD;

(v) Lashkar‑e‑Taiba;

(w) Lashkar‑e‑Tayyaba;

(x) Lashkar‑e‑Toiba;

(y) Lashkar‑i‑Tayyaba;

(z) Lashkar‑i‑Toiba;

(za) Lashkar‑Tayyiba;

(zb) LeT;

(zc) LT;

(zd) Paasban‑e‑Ahle‑Hadis;

(ze) Paasban‑e‑Kashmir;

(zf) Paasban‑i‑Ahle‑Hadith;

(zg) Party of the Calling;

(zh) Party of Preachers;

(zi) Pasban‑e‑Ahle‑Hadith;

(zj) Pasban‑e‑Kashmir;

(zk) Soldiers of the Pure;

(zl) Tehreek‑e‑Tahafuz Qibla Awal.

4W Terrorist organisations—Kurdistan Workers Party (PKK)

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Kurdistan Workers Party is specified.

(2) For subregulation (1), Kurdistan Workers Party is also known by the following names:

(a) Freedom and Democratic Congress of Kurdistan;

(b) Hezan Parastina Gel (HPG);

(c) KADEK;

(d) KG;

(e) KHK;

(f) Kongra Gel;

(g) Kongra Gele Kurdistan;

(h) Kurdish Freedom Falcons;

(i) Kurdish Liberation Hawks;

(j) Kurdistan Freedom and Democracy Congress;

(k) Kurdistan Freedom Brigade;

(l) Kurdistan Freedom Hawks;

(m) Kurdistan Halk Kongresi;

(n) Kurdistan Labor Party;

(o) Kurdistan Ozgurluk Sahinleri;

(p) Kurdistan People’s Congress;

(q) New PKK;

(r) Partiya Karkeren Kurdistan;

(s) People’s Congress of Kurdistan;

(t) People’s Defence Force;

(u) PKK;

(v) TAK;

(w) Teyrbazên Azadiya Kurdistan.

4X Terrorist organisations—Al‑Shabaab

(1) For paragraph (b) of the definition of ***terrorist organisation*** in subsection 102.1(1) of the Code, the organisation known as Al‑Shabaab is specified.

(2) For subregulation (1), Al‑Shabaab is also known by the following names:

(a) Al‑Shabaab Al‑Islaam;

(b) Al‑Shabaab al‑Islamiya;

(c) Al‑Shabaab Al‑Jihaad;

(d) Al‑Shabab;

(e) Ash‑shabaab;

(f) Harakat al‑Shabaab al‑Mujahideen;

(g) Harakat Shabab Al‑Mujahidin;

(h) Harakatul Shabaab al‑Mujaahidiin;

(i) Hisb’ul Shabaab;

(j) Hizbul Shabaab;

(k) HSM;

(l) Mujaahidiin Youth Movement;

(m) Mujahideen Youth Movement;

(n) Mujahidin Al‑Shabaab Movement;

(o) Mujahidin Youth Movement;

(p) MYM;

(q) Shabaab;

(r) The Popular Resistance Movement in the Land of the Two Migrations;

(s) The Unity of Islamic Youth;

(t) The Youth;

(u) Young Mujahideen Movement;

(v) Young Mujahideen Movement in Somalia, Youth Wing.

Part 3—Dangers to the community

Division 3.1—Cross‑border firearms trafficking

5 Cross‑border firearms trafficking

For the definition of ***firearm law*** in subsections 360.2(3) and 360.3(2) of the Code, the Acts, and any regulations made under those Acts, mentioned in Schedule 2 are prescribed.

Division 3.2—Serious drugs and precursors

5A Controlled drugs

(1) For paragraph 301.1(1)(a) of the Code, a drug listed in column 1 of an item in Schedule 3 is a controlled drug.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity listed in column 2 of an item in Schedule 3 is the commercial quantity of the controlled drug listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity listed in column 3 of an item in Schedule 3 is the marketable quantity of the controlled drug listed in column 1 of that item.

(4) For paragraph (a) of item 1 of the table in section 301.12 of the Code, the quantity listed in column 4 of an item in Schedule 3 is the trafficable quantity of the controlled drug listed in column 1 of that item.

5B Controlled plants

(1) For paragraph 301.2(1)(a) of the Code, a growing plant listed in column 1 of an item in the following table is a controlled plant.

| Controlled plants and quantities | | | | |
| --- | --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 | Column 4 |
|  | Controlled plant | Commercial quantity | Marketable quantity | Trafficable quantity |
| 1 | Any plant of the genus *Cannabis* | 250 kg or 1,000 plants | 25 kg or 100 plants | 250 g or 10 plants |

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, a quantity listed in column 2 of an item in the table in subregulation (1) is a commercial quantity of the controlled plant listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, a quantity listed in column 3 of an item in the table in subregulation (1) is a marketable quantity of the controlled plant listed in column 1 of that item.

(4) For paragraph (a) of item 1 of the table in section 301.12 of the Code, a quantity listed in column 4 of an item in the table in subregulation (1) is the trafficable quantity of the controlled plant listed in column 1 of that item.

5C Controlled precursors

(1) For paragraph 301.3(1)(a) of the Code, a precursor listed in column 1 of an item in the following table is a controlled precursor.

| Controlled precursors and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Controlled precursor | Commercial quantity (kilograms) | Marketable quantity (grams) |
| 1 | Ephedrine | 1.2 | 400.0 |
| 2 | Ergometrine | 0.006 | 0.15 |
| 3 | Ergotamine | 0.01 | 0.25 |
| 4 | Isosafrole | 1.45 | 290.0 |
| 5 | Lysergic acid | 0.003 | 0.075 |
| 6 | 3,4‑Methylenedioxyphenylacetic acid | 1.5 | 300.0 |
| 7 | 3,4‑Methylenedioxyphenyl‑2‑propanone | 0.75 | 150.0 |
| 8 | Phenylacetic acid | 4.05 | 1,350.0 |
| 9 | Phenylpropanolamine | 1.2 | 400.0 |
| 10 | Phenyl‑2‑propanone | 2.03 | 675.0 |
| 11 | Piperonal | 1.6 | 320.0 |
| 12 | Pseudoephedrine | 1.2 | 400.0 |
| 13 | Safrole | 2.85 | 570.0 |

Note: A salt or ester of a precursor listed in column 1 of the table is also a controlled precursor: see paragraph 301.3(b) of the Code.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity listed in column 2 of an item in the table in subregulation (1) is the commercial quantity of the controlled precursor listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity listed in column 3 of an item in the table in subregulation (1) is the marketable quantity of the controlled precursor listed in column 1 of that item.

5D Border controlled drugs

(1) For paragraph 301.4(a) of the Code, a drug listed in column 1 of an item in Schedule 4 is a border controlled drug.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity listed in column 2 of an item in Schedule 4 is the commercial quantity of the border controlled drug listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity listed in column 3 of an item in Schedule 4 is the marketable quantity of the border controlled drug listed in column 1 of that item.

5E Border controlled plants

(1) For paragraph 301.5(a) of the Code, a growing plant listed in column 1 of an item in the following table is a border controlled plant.

| Border controlled plants and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Border controlled plant | Commercial quantity | Marketable quantity |
| 1 | Any plant of the genus *Cannabis* | 250 kg or 1,000 plants | 25 kg or 100 plants |
| 2 | Any plant of the genus *Erythroxylon* (also known as Erythroxylum) from which cocaine can be extracted either directly or by chemical transformation |  | 80 kg |
| 3 | Any plant of the genus *Lophophora* |  |  |
| 4 | Any plant of the species *Papaver bracteatum* |  | 10 kg |
| 5 | Any plant of the species *Papaver somniferum* |  | 10 kg |
| 6 | Any plant of the species *Piptagenia peregrine* |  |  |
| 7 | Any plant of the species *Psilocybe* |  |  |

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, a quantity (if any) listed in column 2 of an item in the table in subregulation (1) is a commercial quantity of the border controlled plant listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, a quantity (if any) listed in column 3 of an item in the table in subregulation (1) is a marketable quantity of the border controlled plant listed in column 1 of that item.

5F Border controlled precursors

(1) For paragraph 301.6(1)(a) of the Code, a precursor listed in column 1 of an item in the following table is a border controlled precursor.

| Border controlled precursors and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Border controlled precursor | Commercial quantity (kilograms) | Marketable quantity (grams) |
| 1 | N‑Acetylanthranilic acid |  |  |
| 2 | Any plant of the species *Ephedra* |  |  |
| 3 | Ephedrine | 1.2 | 3.2 |
| 4 | Ergometrine | 0.006 | 0.006 |
| 5 | Ergotamine | 0.01 | 0.01 |
| 6 | Isosafrole | 1.45 | 1.45 |
| 7 | Lysergic acid | 0.003 | 0.003 |
| 8 | 3,4‑Methylenedioxyphenyl‑2‑propanone | 0.75 | 0.75 |
| 9 | Phenylacetic acid | 4.05 | 10.8 |
| 10 | Phenylpropanolamine | 1.2 | 3.2 |
| 11 | Phenyl‑2‑propanone | 2.03 | 5.4 |
| 12 | Piperonal | 1.6 | 1.6 |
| 13 | Pseudoephedrine | 1.2 | 3.2 |
| 14 | Safrole | 2.85 | 2.85 |

Note: A salt or ester of a precursor listed in column 1 of the table and an immediate precursor of a precursor listed in column 1 of the table is a border controlled precursor: see paragraphs 301.6(1)(b) and (c) of the Code.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity (if any) listed in column 2 of an item in the table in subregulation (1) is the commercial quantity of the border controlled precursor listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity (if any) listed in column 3 of an item in the table in subregulation (1) is the marketable quantity of the border controlled precursor listed in column 1 of that item.

Part 4—National infrastructure

6 Dangerous goods

For subparagraph 471.15(1)(b)(ii) of the Code, the following substances and things must not, without exception, be carried by post:

(a) gas that is so toxic or corrosive to humans as to pose a hazard to health;

(b) a thermally unstable substance that is likely to undergo a strongly exothermic decomposition;

(c) a substance that ignites or self‑heats when in contact with air.

Schedule 1—Corresponding State preventative detention law

(regulation 4)

Part 1—Laws of a State or Territory

| Item | Declared laws |
| --- | --- |
| 1 | *Terrorism (Preventative Detention) Act 2005* (Qld) |
| 1A | *Terrorism (Preventative Detention) Act 2006* (WA) |
| 2 | *Terrorism (Preventative Detention) Act 2005* (SA) |
| 3 | *Terrorism (Preventative Detention) Act 2005* (Tas) |

Part 2—Particular provisions of a law of a State or Territory

| Item | Declared provisions |
| --- | --- |
| 1 | Part 2A, *Terrorism (Police Powers) Act 2002* (NSW) |
| 2 | Part 2A, **Terrorism (Community Protection) Act 2003** (Vic) |
| 3 | Part 2, *Terrorism (Extraordinary Temporary Powers) Act 2006* (ACT) |
| 4 | Part 2B, *Terrorism (Emergency Powers) Act* (NT) |

Schedule 2—Cross‑border firearms trafficking

(regulation 5)

| Item | Act |
| --- | --- |
| 1 | *Firearms Act 1996* (NSW) |
| 2 | **Firearms Act 1996** (Vic) |
| 3 | *Weapons Act 1990* (Qld) |
| 4 | *Firearms Act 1973* (WA) |
| 5 | Firearms Act 1977 (SA) |
| 6 | *Firearms Act 1996* (Tas) |
| 7 | *Firearms Act 1996* (ACT) |
| 8 | *Firearms Act 1997* (NT) |
| 9 | *Firearms Act 1997* (Norfolk Island) |

Schedule 3—Controlled drugs

Note: See regulation 5A.

| Controlled drugs and quantities | | | | |
| --- | --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 | Column 4 |
|  | Controlled drug | Commercial quantity (kilograms) | Marketable quantity (grams) | Trafficable quantity (grams) |
| 1 | Acetorphine | 2.0 | 250.0 | 2.0 |
| 2 | Acetyl‑alpha‑methylfentanyl | 0.005 | 2.5 | 0.005 |
| 3 | 4‑Acetoxy‑N, N‑dimethyltryptamine (4‑AcO‑DMT) | 2.0 | 250.0 | 2.0 |
| 4 | 4‑Acetoxy‑N‑methyl‑N‑ethyltryptamine (4‑AcO‑MET) | 2.0 | 250.0 | 2.0 |
| 5 | Acetylcodeine | 2.0 | 250.0 | 2.0 |
| 6 | Acetyldihydrocodeine | 2.0 | 250.0 | 2.0 |
| 7 | Acetylmethadol | 2.0 | 250.0 | 2.0 |
| 8 | Allylprodine | 2.0 | 250.0 | 2.0 |
| 9 | Alphacetylmethadol | 10.0 | 5,000.0 | 10.0 |
| 10 | Alphameprodine | 0.2 | 100.0 | 0.2 |
| 11 | Alphamethadol | 0.2 | 100.0 | 0.2 |
| 12 | alpha‑Methylfentanyl | 0.005 | 2.5 | 0.005 |
| 13 | alpha‑Methylthiofentanyl | 0.005 | 2.5 | 0.005 |
| 14 | alpha‑Pyrrolidinobutiophenone (α‑PBP) | 0.75 | 250.0 | 0.75 |
| 15 | alpha‑Pyrrolidinopropiophenone (α‑PPP) | 0.75 | 250.0 | 0.75 |
| 16 | alpha‑Pyrrolidinovalerophenone (α‑PVP) | 0.75 | 250.0 | 0.75 |
| 17 | Alphaprodine | 25.0 | 12,500.0 | 25.0 |
| 18 | 5‑(2‑Aminopropyl)‑2,3‑dihydro‑1h‑indene (5‑APDI) | 0.75 | 250.0 | 0.75 |
| 19 | 6‑(2‑Aminopropyl)‑2,3‑dihydrobenzofuran (6‑APDB) | 0.75 | 250.0 | 0.75 |
| 20 | Amphetamine | 0.75 | 250.0 | 2.0 |
| 21 | Anileridine | 25.0 | 12,500.0 | 25.0 |
| 22 | Barbiturates | 5.0 |  | 5.0 |
| 23 | Benzethidine | 10.0 | 5,000.0 | 10.0 |
| 24 | 1‑(Benzofuran‑6‑yl) propan‑2‑amine (6‑APB) | 0.75 | 250.0 | 0.75 |
| 25 | Benzoylecgonine | 2.0 | 250.0 | 2.0 |
| 26 | Benzylmorphine | 5.0 | 2,500.0 | 5.0 |
| 27 | Benzylpiperazine | 0.75 | 250.0 | 2.0 |
| 28 | Betacetylmethadol | 5.0 | 2,500.0 | 5.0 |
| 29 | beta‑Hydroxyfentanyl | 0.005 | 2.5 | 0.005 |
| 30 | beta‑Hydroxy‑3‑methylfentanyl | 0.005 | 2.5 | 0.005 |
| 31 | beta‑Keto‑methylbenzodioxolylpentanamine (pentylone) | 0.75 | 250.0 | 0.75 |
| 32 | beta‑Keto‑N‑methyl‑3,4‑benzodioxyolylbutanamine (butylone) | 0.75 | 250.0 | 0.75 |
| 33 | Betameprodine | 5.0 | 2,500.0 | 5.0 |
| 34 | Betamethadol | 5.0 | 2,500.0 | 5.0 |
| 35 | Betaprodine | 5.0 | 2,500.0 | 5.0 |
| 36 | Bezitramide | 5.0 | 2,500.0 | 5.0 |
| 37 | 2‑Bromoamphetamine | 0.75 | 250.0 | 0.75 |
| 38 | 3‑Bromoamphetamine | 0.75 | 250.0 | 0.75 |
| 39 | 4‑Bromoamphetamine | 0.75 | 250.0 | 0.75 |
| 40 | 4‑Bromo‑2,5‑dimethoxyamphetamine | 0.5 | 100.0 | 0.5 |
| 41 | 2‑Bromo‑5‑methoxymethcathinone | 0.75 | 250.0 | 0.75 |
| 42 | 2‑Bromomethamphetamine | 0.75 | 250.0 | 0.75 |
| 43 | 3‑Bromomethamphetamine | 0.75 | 250.0 | 0.75 |
| 44 | 4‑Bromomethamphetamine | 0.75 | 250.0 | 0.75 |
| 45 | 2‑Bromomethcathinone | 0.75 | 250.0 | 0.75 |
| 46 | 3‑Bromomethcathinone | 0.75 | 250.0 | 0.75 |
| 47 | 4‑Bromomethcathinone | 0.75 | 250.0 | 0.75 |
| 48 | Bufotenine | 2.0 | 250.0 | 2.0 |
| 49 | Bupropion | 0.75 | 250.0 | 0.75 |
| 50 | Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) | 125.0 | 25,000.0 | 250.0 |
| 51 | Cannabis resin | 125.0 | 25,000.0 | 20.0 |
| 52 | Cathinone | 0.75 | 250.0 | 0.75 |
| 53 | 1‑(4‑Chloro‑2,5‑dimethoxyphenyl)‑2‑ethenamine (2C‑C) | 0.5 | 100.0 | 0.5 |
| 54 | 2‑Chloroamphetamine | 0.75 | 250.0 | 0.75 |
| 55 | 3‑Chloroamphetamine | 0.75 | 250.0 | 0.75 |
| 56 | 4‑Chloroamphetamine | 0.75 | 250.0 | 0.75 |
| 57 | 2‑Chloromethamphetamine | 0.75 | 250.0 | 0.75 |
| 58 | 3‑Chloromethamphetamine | 0.75 | 250.0 | 0.75 |
| 59 | 4‑Chloromethamphetamine | 0.75 | 250.0 | 0.75 |
| 60 | 4‑Chloro‑N‑ethylamphetamine | 0.75 | 250.0 | 0.75 |
| 61 | 2‑Chloromethcathinone | 0.75 | 250.0 | 0.75 |
| 62 | 3‑Chloromethcathinone | 0.75 | 250.0 | 0.75 |
| 63 | 4‑Chloromethcathinone | 0.75 | 250.0 | 0.75 |
| 64 | 4‑Chlorophenyl‑1‑methoxypropan‑2‑amine | 0.75 | 250.0 | 0.75 |
| 65 | Chlorphentermine | 2.0 | 250.0 | 2.0 |
| 66 | Clonitazene | 5.0 | 100.0 | 5.0 |
| 67 | Cocaine | 2.0 | 250.0 | 2.0 |
| 68 | Codeine | 10.0 | 5,000.0 | 10.0 |
| 69 | Codeine‑N‑oxide | 10.0 | 5,000.0 | 10.0 |
| 70 | Codoxime | 10.0 | 5,000.0 | 10.0 |
| 71 | Desomorphine | 2.0 | 250.0 | 2.0 |
| 72 | Dexamphetamine | 2.0 | 250.0 | 2.0 |
| 73 | Dextromoramide | 2.0 | 250.0 | 2.0 |
| 74 | Diampromide | 5.0 | 2,500.0 | 5.0 |
| 75 | Diethylpropion (N, N‑Diethylcathinone) | 5.0 | 2,500.0 | 5.0 |
| 76 | Diethylthiambutene | 5.0 | 2,500.0 | 5.0 |
| 77 | N,N‑Diethyltryptamine | 2.0 | 250.0 | 2.0 |
| 78 | Difenoxin | 2.0 | 250.0 | 2.0 |
| 79 | 1‑(2,3‑Dihydro‑1‑benzofuran‑5‑yl)propan‑2‑amine (5‑APDB) | 0.75 | 250.0 | 0.75 |
| 80 | Dihydrocodeine | 10.0 | 5,000.0 | 10.0 |
| 81 | Dihydromorphine | 10.0 | 5,000.0 | 10.0 |
| 82 | Dimenoxadol | 10.0 | 5,000.0 | 10.0 |
| 83 | Dimepheptanol | 10.0 | 5,000.0 | 10.0 |
| 84 | 2,5‑Dimethoxy‑4‑bromophenethylamine (2C‑B) | 0.5 | 100.0 | 0.5 |
| 85 | 2,5‑Dimethoxy‑4‑ethylphenethylamine (2C‑E) | 0.5 | 100.0 | 0.5 |
| 86 | 2,5‑Dimethoxy‑4‑iodophenethylamine (2C‑I) | 0.5 | 100.0 | 0.5 |
| 87 | 2,5‑Dimethoxy‑4‑methylamphetamine (STP, DOM) | 0.75 | 250 | 0.75 |
| 88 | 2,5‑Dimethoxy‑4‑methylphenethylamine (2C‑D) | 0.5 | 100.0 | 0.5 |
| 89 | 2,5‑Dimethoxy‑4‑nitrophenethylamine (2C‑N) | 0.5 | 100.0 | 0.5 |
| 90 | 2,5‑Dimethoxy‑4‑(n)‑propylphenethylamine (2C‑P) | 0.5 | 100.0 | 0.5 |
| 91 | 3,4‑Dimethoxymethcathinone | 0.75 | 250.0 | 0.75 |
| 92 | 1‑Dimethylamino‑1,2‑diphenylethane | 5.0 | 2,500.0 | 5.0 |
| 93 | N,N‑Dimethylamphetamine | 0.75 | 250.0 | 0.75 |
| 94 | N, N‑Dimethylcathinone | 0.75 | 250.0 | 0.75 |
| 95 | 1,1‑Dimethylheptyl‑11‑hydroxytetrahydrocannabinol (HU‑210) | 5.0 | 1,000.0 | 5.0 |
| 96 | 3,4‑Dimethylmethcathinone | 0.75 | 250.0 | 0.75 |
| 97 | Dimethylthiambutene | 20.0 | 10,000.0 | 20.0 |
| 98 | N,N‑Dimethyltryptamine | 2.0 | 250.0 | 2.0 |
| 99 | Dioxaphetyl butyrate | 2.0 | 250.0 | 2.0 |
| 100 | Diphenoxylate | 2.0 | 250.0 | 2.0 |
| 101 | Dipipanone | 10.0 | 5,000.0 | 10.0 |
| 102 | Drotebanol | 2.0 | 250.0 | 2.0 |
| 103 | Ecgonine | 10.0 | 5,000.0 | 10.0 |
| 104 | Ethchlorvynol | 50.0 |  | 50.0 |
| 105 | Ethinamate | 50.0 |  | 50.0 |
| 106 | N‑Ethylcathinone | 0.75 | 250.0 | 0.75 |
| 107 | Ethylmethylthiambutene | 10.0 | 5,000.0 | 10.0 |
| 108 | Ethylmorphine | 2.0 | 250.0 | 2.0 |
| 109 | 3‑(2‑Ethylphenyl)‑2‑methyl‑quinazolin‑4‑one (Etaqualone) | 5.0 |  | 5.0 |
| 110 | Etonitazene | 5.0 | 2,500.0 | 5.0 |
| 111 | Etorphine | 5.0 | 2,500.0 | 5.0 |
| 112 | Etoxeridine | 5.0 | 2,500.0 | 5.0 |
| 113 | Fentanyl | 0.005 | 2.5 | 0.005 |
| 114 | 4‑Fluoro‑2,5‑dimethoxyphenethylamine (2C‑F) | 0.5 | 100.0 | 0.5 |
| 115 | 2‑Fluoroamphetamine | 0.75 | 250.0 | 0.75 |
| 116 | 3‑Fluoroamphetamine | 0.75 | 250.0 | 0.75 |
| 117 | 4‑Fluoroamphetamine | 0.75 | 250.0 | 0.75 |
| 118 | 2‑Fluoromethamphetamine | 0.75 | 250.0 | 0.75 |
| 119 | 3‑Fluoromethamphetamine | 0.75 | 250.0 | 0.75 |
| 120 | 4‑Fluoromethamphetamine | 0.75 | 250.0 | 0.75 |
| 121 | 2‑Fluoromethcathinone | 0.75 | 250.0 | 0.75 |
| 122 | 3‑Fluoromethcathinone | 0.75 | 250.0 | 0.75 |
| 123 | 4‑Fluoromethcathinone | 0.75 | 250.0 | 0.75 |
| 124 | Furethidine | 1.0 | 500.0 | 1.0 |
| 125 | Gammabutyrolactone (GBL) | 1.0 | 250.0 | 0.5 |
| 126 | Glutethimide | 50.0 |  | 50.0 |
| 127 | Heroin (diacetylmorphine) | 1.5 | 250.0 | 2.0 |
| 128 | Hydrocodone | 2.0 | 250.0 | 2.0 |
| 129 | Hydromorphinol | 2.0 | 250.0 | 2.0 |
| 130 | Hydromorphone | 2.0 | 250.0 | 2.0 |
| 131 | Hydroxyamphetamine | 2.0 | 250.0 | 2.0 |
| 132 | 4‑Hydroxybutanoic acid (GHB) | 1.0 | 250.0 | 0.5 |
| 133 | p‑Hydroxyephedrine | 2.0 | 250.0 | 2.0 |
| 134 | Hydroxypethidine | 0.75 | 250.0 | 0.75 |
| 135 | 2‑Iodoamphetamine | 0.75 | 250.0 | 0.75 |
| 136 | 3‑Iodoamphetamine | 0.75 | 250.0 | 0.75 |
| 137 | 4‑Iodoamphetamine | 0.75 | 250.0 | 0.75 |
| 138 | 2‑Iodomethamphetamine | 0.75 | 250.0 | 0.75 |
| 139 | 3‑Iodomethamphetamine | 0.75 | 250.0 | 0.75 |
| 140 | 4‑Iodomethamphetamine | 0.75 | 250.0 | 0.75 |
| 141 | 2‑Iodomethcathinone | 0.75 | 250.0 | 0.75 |
| 142 | 3‑Iodomethcathinone | 0.75 | 250.0 | 0.75 |
| 143 | 4‑Iodomethcathinone | 0.75 | 250.0 | 0.75 |
| 144 | Isomethadone | 2.0 | 250.0 | 2.0 |
| 145 | 4‑Isopropoxy‑2,5‑dimethoxyphenethylamine (2C‑O‑4) | 0.5 | 100.0 | 0.5 |
| 146 | Ketamine | 1.0 | 500.0 | 3.0 |
| 147 | Ketobemidone | 2.0 | 250.0 | 2.0 |
| 148 | Levophenacylmorphan | 2.0 | 250.0 | 2.0 |
| 149 | Levomethorphan | 2.0 | 250.0 | 2.0 |
| 150 | Levorphanol, but not including dextrorphan | 1.0 | 500.0 | 1.0 |
| 151 | Lysergamides | 0.01 |  | 0.01 |
| 152 | Lysergide (LSD) | 0.002 | 0.05 | 0.002 |
| 153 | Meprobamate | 50.0 |  | 50.0 |
| 154 | Mescaline | 7.5 | 3.75 | 7.5 |
| 155 | Metazocine | 7.0 | 3,500.0 | 7.0 |
| 156 | Methadone | 2.0 | 250.0 | 2.0 |
| 157 | Methamphetamine | 0.75 | 250.0 | 2.0 |
| 158 | Methaqualone | 5.0 |  | 5.0 |
| 159 | Methcathinone | 0.75 | 250.0 | 2.0 |
| 160 | Methorphan, but not including dextromethorphan | 2.0 | 250.0 | 2.0 |
| 161 | 4’‑Methoxy‑alpha‑pyrrolidinopropiophenone (MOPPP) | 0.75 | 250.0 | 0.75 |
| 162 | 4‑Methoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 163 | 4‑Methoxymethamphetamine | 0.75 | 250.0 | 0.75 |
| 164 | 4‑Methoxymethcathinone | 0.75 | 250.0 | 0.75 |
| 165 | 4’‑Methyl‑alpha‑pyrrolidinobutiophenone (MPBP) | 0.75 | 250.0 | 0.75 |
| 166 | 4’‑Methyl‑alpha‑pyrrolidinohexiophenone (MPHP) | 0.75 | 250.0 | 0.75 |
| 167 | 4’‑Methyl‑alpha‑pyrrolidinopropiophenone (MPPP) | 0.75 | 250.0 | 0.75 |
| 168 | N‑Methyl butylone | 0.75 | 250.0 | 0.75 |
| 169 | 2‑Methylamino‑1‑phenylbutan‑1‑ one (buphedrone) | 0.75 | 250.0 | 0.75 |
| 170 | 4‑Methylamphetamine | 0.75 | 250.0 | 0.75 |
| 171 | 3,4‑Methylenedioxyamphetamine (MDA) | 0.75 | 100.0 | 0.5 |
| 172 | 4‑Methylethcathinone | 0.75 | 250.0 | 0.75 |
| 173 | 3,4‑Methylenedioxymethamphetamine (MDMA) | 0.5 | 100.0 | 0.5 |
| 174 | Methyldesorphine | 2.0 | 250.0 | 2.0 |
| 175 | Methyldihydromorphine | 2.0 | 250.0 | 2.0 |
| 176 | 3,4‑Methylenedioxyethcathinone (MDEC) | 0.75 | 250.0 | 0.75 |
| 177 | 3,4‑Methylenedioxymethcathinone (MDMC) | 0.75 | 250.0 | 0.75 |
| 178 | 3,4‑Methylenedioxypyrovalerone (MDPV) | 0.75 | 250.0 | 0.75 |
| 179 | 3’,4’‑Methylenedioxy‑alpha‑pyrrolidinobutiophenone (MDPBP) | 0.75 | 250.0 | 0.75 |
| 180 | 3’,4’‑Methylenedioxy‑alpha‑pyrrolidinopropiophenone (MDPPP) | 0.75 | 250.0 | 0.75 |
| 181 | 3‑Methylfentanyl | 0.005 | 2.5 | 0.005 |
| 182 | 4‑Methylmethamphetamine | 0.75 | 250.0 | 0.75 |
| 183 | 4‑Methylmethcathinone (4‑MMC) | 0.75 | 250.0 | 2.0 |
| 184 | Methylphenidate | 2.0 | 250.0 | 2.0 |
| 185 | 1‑Methyl‑4‑phenyl‑4‑propionoxypiperidine (MPPP) | 2.0 | 250.0 | 2.0 |
| 186 | 4‑Methylthioamphetamine (4‑MTA) | 0.75 | 250.0 | 0.75 |
| 187 | 4‑Methylthiobutylamphetamine (4‑MTBA) | 0.75 | 250.0 | 0.75 |
| 188 | 4‑Methylthiodimethamphetamine (4‑MTDMA) | 0.75 | 250.0 | 0.75 |
| 189 | 4‑Methylthioethylamphetamine (4‑MTEA) | 0.75 | 250.0 | 0.75 |
| 190 | 3‑Methylthiofentanyl | 0.005 | 2.5 | 0.005 |
| 191 | 4‑Methylthiomethamphetamine (4‑MTMA) | 0.75 | 250.0 | 0.75 |
| 192 | 4‑Methylthiopropylamphetamine (4‑MTPA) | 0.75 | 250.0 | 0.75 |
| 193 | Methyprylon | 50.0 |  | 50.0 |
| 194 | Metopon | 2.0 | 250.0 | 2.0 |
| 195 | Monoacetylmorphines | 2.0 | 250.0 | 2.0 |
| 196 | Moramide | 2.0 | 250.0 | 2.0 |
| 197 | Morphan, but not including dextrorphan | 2.0 | 250.0 | 2.0 |
| 198 | Morpheridine | 2.0 | 250.0 | 2.0 |
| 199 | Morphine | 1.5 | 250.0 | 1.5 |
| 200 | Morphine‑N‑oxide | 2.0 | 250.0 | 2.0 |
| 201 | Myrophine | 20.0 |  | 20.0 |
| 202 | Nicocodine | 2.0 | 250.0 | 2.0 |
| 203 | Nicodicodine | 2.0 | 250.0 | 2.0 |
| 204 | Nicomorphine | 2.0 | 250.0 | 2.0 |
| 205 | Noracymethadol | 2.0 | 250.0 | 2.0 |
| 206 | Norcodeine | 2.0 | 250.0 | 2.0 |
| 207 | Norlevorphanol | 2.0 | 250.0 | 2.0 |
| 208 | Normethadone | 5.0 | 2,500.0 | 5.0 |
| 209 | Normorphine | 20.0 |  | 20.0 |
| 210 | Norpipanone | 10.0 | 5,000.0 | 10.0 |
| 211 | Opium | 20.0 | 10,000.0 | 20.0 |
| 212 | Oripavine | 2.0 | 250.0 | 2.0 |
| 213 | Oxycodone | 5.0 | 2,500.0 | 5.0 |
| 214 | Oxymorphone | 2.0 | 250.0 | 2.0 |
| 215 | para‑Fluorofentanyl | 0.005 | 2.5 | 0.005 |
| 216 | Pentazocine | 20.0 |  | 20.0 |
| 217 | Pethidine | 10.0 | 5,000.0 | 10.0 |
| 218 | Phenadoxone | 10.0 | 5,000.0 | 10.0 |
| 219 | Phenampromide | 10.0 | 5,000.0 | 10.0 |
| 220 | Phenazocine | 1.0 | 500.0 | 1.0 |
| 221 | Phencyclidine | 2.0 | 250.0 | 2.0 |
| 222 | Phendimetrazine | 5.0 | 2,500.0 | 5.0 |
| 223 | Phenmetrazine | 5.0 | 2,500.0 | 5.0 |
| 224 | Phenomorphan | 5.0 | 2,500.0 | 5.0 |
| 225 | Phenoperidine | 1.0 | 500.0 | 1.0 |
| 226 | Phentermine | 5.0 | 2,500.0 | 5.0 |
| 227 | 1‑Phenylethyl‑4‑phenyl‑4‑acetoxypiperidine (PEPAP) | 2.0 | 250.0 | 2.0 |
| 228 | Pholcodine | 5.0 | 2,500.0 | 5.0 |
| 229 | Piminodine | 10.0 | 5,000.0 | 10.0 |
| 230 | Pipradrol | 1.0 | 500.0 | 1.0 |
| 231 | Piritramide | 1.0 | 500.0 | 1.0 |
| 232 | Proheptazine | 1.0 | 500.0 | 1.0 |
| 233 | Properidine | 25.0 | 12,500.0 | 25.0 |
| 234 | Propiram | 10.0 | 5,000.0 | 10.0 |
| 235 | Psilocine | 2.0 | 1,000.0 | 2.0 |
| 236 | Psilocybine | 2.0 | 1,000.0 | 2.0 |
| 237 | Pyrovalerone | 0.75 | 250.0 | 0.75 |
| 238 | Tetrahydrocannabinols (THC) | 5.0 | 1,000.0 | 2.0 |
| 239 | Thebacon | 2.0 | 250.0 | 2.0 |
| 240 | Thebaine | 2.0 | 250.0 | 2.0 |
| 241 | Thiofentanyl | 0.005 | 2.5 | 0.005 |
| 242 | 2,4,5‑Trimethoxyphenethylamine (2C‑O) | 0.5 | 100.0 | 0.5 |
| 243 | Trimeperidine | 10.0 | 5,000.0 | 10.0 |
| 244 | 2,3,4‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 245 | 2,3,5‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 246 | 2,3,6‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 247 | 2,4,5‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 248 | 2,4,6‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 249 | 3,4,5‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |

Note: A drug analogue of a drug listed in column 1 of the table is a controlled drug: see paragraph 301.1(b) of the Code.

Schedule 4—Border controlled drugs

Note: See regulation 5D.

| Border controlled drugs and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Border controlled drug | Commercial quantity (kilograms) | Marketable quantity (grams) |
| 1 | Acetorphine | 2.0 | 2.0 |
| 2 | Acetyl‑alpha‑methylfentanyl | 0.005 | 0.005 |
| 3 | Acetylcodeine | 2.0 | 2.0 |
| 4 | Acetyldihydrocodeine | 2.0 | 2.0 |
| 5 | Acetylmethadol | 2.0 | 2.0 |
| 6 | Allylprodine | 2.0 | 2.0 |
| 7 | Alphacetylmethadol | 10.0 | 10.0 |
| 8 | Alphameprodine | 0.2 | 0.2 |
| 9 | Alphamethadol | 0.2 | 0.2 |
| 10 | alpha‑Methylfentanyl | 0.005 | 0.005 |
| 11 | alpha‑Methylthiofentanyl | 0.005 | 0.005 |
| 12 | Alphaprodine | 25.0 | 25.0 |
| 13 | Amphecloral | 2.0 | 2.0 |
| 14 | 3‑(2‑Aminopropyl)indole (alpha‑methyltryptamine (AMT)) | 2.0 | 2.0 |
| 15 | 5‑(2‑Aminopropyl)‑2,3‑dihydro‑1h‑indene (5‑APDI) | 0.75 | 0.5 |
| 16 | Amphetamine | 0.75 | 2.0 |
| 17 | Anileridine | 25.0 | 25.0 |
| 18 | Barbiturates | 5.0 | 50.0 |
| 19 | Benzethidine | 10.0 | 10.0 |
| 20 | 1‑(Benzofuran‑6‑yl) propan‑2‑amine (6‑APB) | 0.75 | 0.5 |
| 21 | Benzoylecgonine | 2.0 | 2.0 |
| 22 | Benzylmorphine | 5.0 | 5.0 |
| 23 | Benzylpiperazine | 0.75 | 2.0 |
| 24 | Betacetylmethadol | 5.0 | 5.0 |
| 25 | beta‑Hydroxyfentanyl | 0.005 | 0.005 |
| 26 | beta‑Hydroxy‑3‑methylfentanyl | 0.005 | 0.005 |
| 27 | beta‑Keto‑N‑methyl‑3,4‑benzodioxyolylbutanamine (butylone) | 0.75 | 2.0 |
| 28 | Betameprodine | 5.0 | 5.0 |
| 29 | Betamethadol | 5.0 | 5.0 |
| 30 | Betaprodine | 5.0 | 5.0 |
| 31 | Bezitramide | 5.0 | 5.0 |
| 32 | 4‑Bromo‑2,5‑dimethoxyamphetamine | 0.5 | 0.5 |
| 32A | 2‑(4‑bromo‑2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑B‑NBOMe) | 0.002 | 0.002 |
| 33 | Bufotenine | 2.0 | 2.0 |
| 34 | Cannabinoids (other than a Cannabinoid of a kind that can be obtained from a plant that is not a Cannabis plant) | 2.0 | 2.0 |
| 35 | Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) | 100.0 | 25,000.0 |
| 36 | Cannabis resin | 50.0 | 20.0 |
| 37 | Cathinone | 0.75 | 2.0 |
| 38 | 1‑(4‑Chloro‑2,5‑dimethoxyphenyl)‑2‑ethenamine (2C‑C) | 0.5 | 0.5 |
| 38A | 2‑(4‑chloro‑2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑C‑NBOMe) | 0.002 | 0.002 |
| 39 | Chlorphentermine | 2.0 | 2.0 |
| 40 | Clonitazene | 5.0 | 5.0 |
| 41 | Cocaine | 2.0 | 2.0 |
| 42 | Codeine | 10.0 | 10.0 |
| 43 | Codeine‑N‑oxide | 10.0 | 10.0 |
| 44 | Codoxime | 10.0 | 10.0 |
| 45 | Desomorphine | 2.0 | 2.0 |
| 46 | Dexamphetamine | 2.0 | 2.0 |
| 47 | Dextromoramide | 2.0 | 2.0 |
| 48 | Diampromide | 5.0 | 5.0 |
| 49 | Diethylpropion (N, N‑Diethylcathinone) | 5.0 | 5.0 |
| 50 | Diethylthiambutene | 5.0 | 5.0 |
| 51 | N,N‑Diethyltryptamine | 2.0 | 2.0 |
| 52 | Difenoxin | 2.0 | 2.0 |
| 53 | Dihydrocodeine | 10.0 | 10.0 |
| 54 | Dihydromorphine | 10.0 | 10.0 |
| 55 | Dimenoxadol | 10.0 | 10.0 |
| 56 | Dimepheptanol | 10.0 | 10.0 |
| 57 | 2,5‑Dimethoxy‑4‑bromophenethylamine (2C‑B) | 0.5 | 0.5 |
| 58 | 2,5‑Dimethoxy‑4‑(n)‑butylthiophenethylamine (2C‑T‑9) | 0.5 | 0.5 |
| 59 | 2,5‑Dimethoxy‑4‑ethylphenethylamine (2C‑E) | 0.5 | 0.5 |
| 60 | 2,5‑Dimethoxy‑4‑ethylthiophenethylamine (2C‑T‑2) | 0.5 | 0.5 |
| 61 | 2,5‑Dimethoxy‑4‑iodophenethylamine (2C‑I) | 0.5 | 0.5 |
| 62 | 2,5‑Dimethoxy‑4‑(β‑isobutylthio)phenethylamine (2C‑T‑17) | 0.5 | 0.5 |
| 63 | 2,5‑Dimethoxy‑4‑isopropylthiophenethylamine (2C‑T‑4) | 0.5 | 0.5 |
| 64 | 2,5‑Dimethoxy‑4‑(β‑methoxyethylthio)phenethylamine (2C‑T‑13) | 0.5 | 0.5 |
| 65 | 2,5‑Dimethoxy‑4‑methylamphetamine (STP, DOM) | 0.75 | 2.0 |
| 66 | 2,5‑Dimethoxy‑4‑methylphenethylamine (2C‑D) | 0.5 | 0.5 |
| 67 | 2,5‑Dimethoxy‑4‑nitrophenethylamine (2C‑N) | 0.5 | 0.5 |
| 68 | 2,5‑Dimethoxy‑4‑(n)‑propylphenethylamine (2C‑P) | 0.5 | 0.5 |
| 69 | 2,5‑Dimethoxy‑4‑n‑propylthiophenethylamine (2C‑T‑7) | 0.5 | 0.5 |
| 69A | 2‑(2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑H‑NBOMe) | 0.002 | 0.002 |
| 70 | 1‑Dimethylamino‑1,2‑diphenylethane | 5.0 | 5.0 |
| 71 | 1,1‑Dimethylheptyl‑11‑hydroxytetrahydrocannabinol (HU‑210) | 5.0 | 2.0 |
| 72 | Dimethylthiambutene | 20.0 | 20.0 |
| 73 | N,N‑Dimethyltryptamine | 2.0 | 2.0 |
| 74 | Dioxaphetyl butyrate | 2.0 | 2.0 |
| 75 | Diphenoxylate | 2.0 | 2.0 |
| 76 | Dipipanone | 10.0 | 10.0 |
| 77 | Drotebanol | 2.0 | 2.0 |
| 78 | Ecgonine | 10.0 | 10.0 |
| 79 | Ethchlorvynol | 50.0 | 50.0 |
| 80 | Ethinamate | 50.0 | 50.0 |
| 81 | Ethylmethylthiambutene | 10.0 | 10.0 |
| 82 | Ethylmorphine | 2.0 | 2.0 |
| 83 | Etonitazene | 5.0 | 5.0 |
| 84 | Etorphine | 5.0 | 5.0 |
| 85 | Etoxeridine | 5.0 | 5.0 |
| 86 | Fentanyl | 0.005 | 0.005 |
| 87 | 4‑Fluoro‑2,5‑dimethoxyphenethylamine (2C‑F) | 0.5 | 0.5 |
| 88 | 4‑(2‑Fluoroethylthio)‑2,5‑dimethoxyphenethylamine (2C‑T‑21) | 0.5 | 0.5 |
| 89 | 1‑(5‑fluoropentyl)‑3‑(2‑iodobenzyl)indole (AM‑694) | 5.0 | 2.0 |
| 90 | Furethidine | 1.0 | 1.0 |
| 91 | Gammabutyrolactone (GBL) | 1.0 | 2.0 |
| 92 | Glutethimide | 50.0 | 50.0 |
| 93 | Harmaline | 5.0 | 2.0 |
| 94 | Harmine | 5.0 | 2.0 |
| 95 | Heroin (diacetylmorphine) | 1.5 | 2.0 |
| 96 | Hydrocodone | 2.0 | 2.0 |
| 97 | Hydromorphinol | 2.0 | 2.0 |
| 98 | Hydromorphone | 2.0 | 2.0 |
| 99 | Hydroxyamphetamine | 2.0 | 2.0 |
| 100 | 4‑Hydroxybutanoic acid (GHB) | 1.0 | 2.0 |
| 101 | 2‑[(1R,3S)‑3‑hydroxycyclohexyl]‑5‑(2‑methyloctan‑2‑yl)phenol (CP 47,497) | 5.0 | 2.0 |
| 102 | 2‑[(1R,3S)‑3‑hydroxycyclohexyl]‑5‑(2‑methylnonan‑2‑yl)phenol (CP 47,497‑C8) | 5.0 | 2.0 |
| 103 | Hydroxypethidine | 5.0 | 5.0 |
| 103A | 2‑(4‑iodo‑2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑I‑NBOMe) | 0.002 | 0.002 |
| 104 | Isomethadone | 2.0 | 2.0 |
| 105 | 4‑Isopropoxy‑2,5‑dimethoxyphenethylamine (2C‑O‑4) | 0.5 | 0.5 |
| 106 | Ketamine | 1.0 | 3.0 |
| 107 | Ketobemidone | 2.0 | 2.0 |
| 108 | Levophenacylmorphan | 2.0 | 2.0 |
| 109 | Levomethorphan | 2.0 | 2.0 |
| 110 | Levorphanol, but not including dextrorphan | 1.0 | 1.0 |
| 111 | Lysergamide | 0.01 | 0.1 |
| 112 | Lysergide (LSD) | 0.002 | 0.002 |
| 113 | Meprobamate | 50.0 | 50.0 |
| 114 | Mescaline | 7.5 | 7.5 |
| 115 | Metazocine | 7.0 | 7.0 |
| 116 | Methadone | 2.0 | 2.0 |
| 117 | Methamphetamine | 0.75 | 2.0 |
| 118 | Methaqualone | 5.0 | 50.0 |
| 119 | Methcathinone | 0.75 | 2.0 |
| 120 | Methorphan, but not including dextromethorphan | 2.0 | 2.0 |
| 121 | 5‑Methoxy‑alpha‑methyltryptamine (5‑MeO‑AMT) | 2.0 | 2.0 |
| 122 | 5‑Methoxy‑N,N‑diisopropyltryptamine (5‑MeO‑DiPT) | 2.0 | 2.0 |
| 123 | 4‑Methoxyamphetamine | 0.75 | 2.0 |
| 124 | 4‑Methoxymethamphetamine | 0.75 | 2.0 |
| 125 | 4‑Methylamphetamine | 0.75 | 2.0 |
| 126 | 3,4‑Methylenedioxyamphetamine (MDA) | 0.75 | 0.5 |
| 127 | 2‑(2‑Methoxyphenyl)‑1‑(1‑pentylindol‑3‑yl)ethanone (JWH‑250) | 5.0 | 2.0 |
| 128 | 3,4‑Methylenedioxymethamphetamine (MDMA) | 0.5 | 0.5 |
| 129 | Methyldesorphine | 2.0 | 2.0 |
| 130 | Methyldihydromorphine | 2.0 | 2.0 |
| 131 | 3,4‑Methylenedioxypyrovalerone (MDPV) | 0.75 | 2.0 |
| 132 | 3‑Methylfentanyl | 0.005 | 0.005 |
| 133 | 4‑Methylmethamphetamine | 0.75 | 2.0 |
| 134 | 4‑Methylmethcathinone (4‑MMC) | 0.75 | 2.0 |
| 135 | Methylphenidate | 2.0 | 2.0 |
| 136 | 1‑Methyl‑4‑phenyl‑4‑propionoxypiperidine (MPPP) | 2.0 | 2.0 |
| 137 | 4‑Methylthio‑2,5‑dimethoxyphenethylamine (2C‑T) | 0.5 | 0.5 |
| 138 | 4‑Methylthioamphetamine (4‑MTA) | 0.75 | 2.0 |
| 139 | 4‑Methylthiobutylamphetamine (4‑MTBA) | 0.75 | 2.0 |
| 140 | 4‑Methylthiodimethamphetamine (4‑MTDMA) | 0.75 | 2.0 |
| 141 | 4‑Methylthioethylamphetamine (4‑MTEA) | 0.75 | 2.0 |
| 142 | 3‑Methylthiofentanyl | 0.005 | 0.005 |
| 143 | 4‑Methylthiomethamphetamine (4‑MTMA) | 0.75 | 2.0 |
| 144 | 4‑Methylthiopropylamphetamine (4‑MTPA) | 0.75 | 2.0 |
| 145 | Methyprylon | 50.0 | 50.0 |
| 146 | Metopon | 2.0 | 2.0 |
| 147 | Monoacetylmorphines | 2.0 | 2.0 |
| 148 | Moramide | 2.0 | 2.0 |
| 149 | Morphan, but not including dextrorphan | 2.0 | 2.0 |
| 150 | Morpheridine | 2.0 | 2.0 |
| 151 | Morphine | 1.5 | 2.0 |
| 152 | Morphine‑N‑oxide | 2.0 | 2.0 |
| 153 | (1‑(2‑Morpholin‑4‑ylethyl)indol‑3‑yl)‑napthalen‑1‑ylmethanone (JWH‑200) | 5.0 | 2.0 |
| 154 | Myrophine | 20.0 | 20.0 |
| 155 | Napthalen‑1‑yl‑(1‑butylindol‑3‑yl)methanone (JWH‑073) | 5.0 | 2.0 |
| 156 | Nicocodine | 2.0 | 2.0 |
| 157 | Nicodicodine | 2.0 | 2.0 |
| 158 | Nicomorphine | 2.0 | 2.0 |
| 159 | Noracymethadol | 2.0 | 2.0 |
| 160 | Norcodeine | 2.0 | 2.0 |
| 161 | Norlevorphanol | 2.0 | 2.0 |
| 162 | Normethadone | 5.0 | 5.0 |
| 163 | Normorphine | 20.0 | 20.0 |
| 164 | Norpipanone | 10.0 | 10.0 |
| 165 | Opium | 20.0 | 20.0 |
| 166 | Oripavine | 2.0 | 2.0 |
| 167 | Oxycodone | 5.0 | 5.0 |
| 168 | Oxymorphone | 2.0 | 2.0 |
| 169 | para‑Fluorofentanyl | 0.005 | 0.005 |
| 170 | Pentazocine | 20.0 | 20.0 |
| 171 | 1‑Pentyl‑3‑(1‑napthoyl)indol (JWH‑018) | 5.0 | 2.0 |
| 172 | Pethidine | 10.0 | 10.0 |
| 173 | 1‑Pentyl‑3‑(4‑methyl‑1‑napthoyl)indole (JWH‑122) | 5.0 | 2.0 |
| 174 | Phenadoxone | 10.0 | 10.0 |
| 175 | Phenampromide | 10.0 | 10.0 |
| 176 | Phenazocine | 1.0 | 1.0 |
| 177 | Phencyclidine | 2.0 | 2.0 |
| 178 | Phendimetrazine | 5.0 | 5.0 |
| 179 | Phenmetrazine | 5.0 | 5.0 |
| 180 | Phenomorphan | 5.0 | 5.0 |
| 181 | Phenoperidine | 1.0 | 1.0 |
| 182 | Phentermine | 5.0 | 5.0 |
| 183 | 1‑Phenylethyl‑4‑phenyl‑4‑acetoxypiperidine (PEPAP) | 2.0 | 2.0 |
| 184 | Pholcodine | 5.0 | 5.0 |
| 185 | Piminodine | 10.0 | 10.0 |
| 186 | Pipradrol | 1.0 | 1.0 |
| 187 | Piritramide | 1.0 | 1.0 |
| 188 | Proheptazine | 1.0 | 1.0 |
| 189 | Properidine | 25.0 | 25.0 |
| 190 | Propiram | 10.0 | 10.0 |
| 191 | Psilocine | 0.1 | 0.1 |
| 192 | Psilocybine | 0.1 | 0.1 |
| 193 | Pyrovalerone | 0.75 | 2.0 |
| 194 | Tetrahydrocannabinols (THC) | 5.0 | 2.0 |
| 195 | Thebacon | 2.0 | 2.0 |
| 196 | Thebaine | 2.0 | 2.0 |
| 197 | Thiofentanyl | 0.005 | 0.005 |
| 198 | 2,4,5‑Trimethoxyphenethylamine (2C‑O) | 0.5 | 0.5 |
| 199 | Trimeperidine | 10.0 | 10.0 |
| 200 | 2,3,4‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 201 | 2,3,5‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 202 | 2,3,6‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 203 | 2,4,5‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 204 | 2,4,6‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 205 | 3,4,5‑Trimethoxyamphetamine | 0.75 | 2.0 |

Note: A drug analogue of a drug listed in column 1 of the table is a border controlled drug: see paragraph 301.4(b) of the Code.

Endnotes

Endnote 1—About the endnotes

The endnotes provide details of the history of this legislation and its provisions. The following endnotes are included in each compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Endnote 5—Uncommenced amendments

Endnote 6—Modifications

Endnote 7—Misdescribed amendments

Endnote 8—Miscellaneous

If there is no information under a particular endnote, the word “none” will appear in square brackets after the endnote heading.

**Abbreviation key—Endnote 2**

The abbreviation key in this endnote sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended the compiled law. The information includes commencement information for amending laws and details of application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision level. It also includes information about any provisions that have expired or otherwise ceased to have effect in accordance with a provision of the compiled law.

**Uncommenced amendments—Endnote 5**

The effect of uncommenced amendments is not reflected in the text of the compiled law but the text of the amendments is included in endnote 5.

**Modifications—Endnote 6**

If the compiled law is affected by a modification that is in force, details of the modification are included in endnote 6.

**Misdescribed amendments—Endnote 7**

An amendment is a misdescribed amendment if the effect of the amendment cannot be incorporated into the text of the compilation. Any misdescribed amendment is included in endnote 7.

**Miscellaneous—Endnote 8**

Endnote 8 includes any additional information that may be helpful for a reader of the compilation.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | pres = present |
| am = amended | prev = previous |
| c = clause(s) | (prev) = previously |
| Ch = Chapter(s) | Pt = Part(s) |
| def = definition(s) | r = regulation(s)/rule(s) |
| Dict = Dictionary | Reg = Regulation/Regulations |
| disallowed = disallowed by Parliament | reloc = relocated |
| Div = Division(s) | renum = renumbered |
| exp = expired or ceased to have effect | rep = repealed |
| hdg = heading(s) | rs = repealed and substituted |
| LI = Legislative Instrument | s = section(s) |
| LIA = *Legislative Instruments Act 2003* | Sch = Schedule(s) |
| mod = modified/modification | Sdiv = Subdivision(s) |
| No = Number(s) | SLI = Select Legislative Instrument |
| o = order(s) | SR = Statutory Rules |
| Ord = Ordinance | Sub‑Ch = Sub‑Chapter(s) |
| orig = original | SubPt = Subpart(s) |
| par = paragraph(s)/subparagraph(s) /sub‑subparagraph(s) |  |

Endnote 3—Legislation history

| Number and year | FRLI registration  or Gazettal | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| 2002 No. 67 | 12 Apr 2002 | 12 Apr 2002 |  |
| 2002 No. 248 | 21 Oct 2002 | 21 Oct 2002 | — |
| 2002 No. 249 | 21 Oct 2002 | 21 Oct 2002 *(a)* | — |
| 2002 No. 250 | 27 Oct 2002 | 27 Oct 2002 | — |
| 2002 No. 269 | 14 Nov 2002 | 14 Nov 2002 | — |
| 2002 No. 270 | 14 Nov 2002 | 14 Nov 2002 | — |
| 2002 No. 271 | 14 Nov 2002 | 14 Nov 2002 | — |
| 2002 No. 272 | 14 Nov 2002 | 14 Nov 2002 | — |
| 2003 No. 30 | 7 Mar 2003 | 7 Mar 2003 | — |
| 2003 No. 43 | 27 Mar 2003 | 27 Mar 2003 | — |
| 2003 No. 59 | 11 Apr 2003 | 11 April 2003 | — |
| 2003 No. 60 | 11 Apr 2003 | 11 April 2003 | — |
| 2003 No. 61 | 11 Apr 2003 | 11 April 2003 | — |
| 2003 No. 62 | 11 Apr 2003 | 11 April 2003 | — |
| 2003 No. 63 | 11 Apr 2003 | 11 April 2003 | — |
| 2003 No. 64 | 11 Apr 2003 | 11 April 2003 | — |
| 2003 No. 184 | 18 July 2003 | 5 June 2003 | — |
| 2003 No. 285 | 9 Nov 2003 | 9 Nov 2003 | — |
| 2004 No. 83 | 3 May 2004 | 3 May 2004 | — |
| 2004 No. 283 | 1 Sept 2004 | 1 Sept 2004 | — |
| 2004 No. 284 | 1 Sept 2004 | 1 Sept 2004 | — |
| 2004 No. 311 | 5 Nov 2004 | 5 Nov 2004 | — |
| 2004 No. 312 | 5 Nov 2004 | 5 Nov 2004 | — |
| 2004 No. 313 | 5 Nov 2004 | 5 Nov 2004 | — |
| 2004 No. 314 | 5 Nov 2004 | 5 Nov 2004 | — |
| 2005 No. 23 | 1 Mar 2005 (*see* F2005L00384) | 2 Mar 2005 | — |
| 2005 No. 36 | 23 Mar 2005 (*see* F2005L00699) | 27 Mar 2005 | — |
| 2005 No. 57 | 8 Apr 2005 (*see* F2005L00703) | 11 Apr 2005 | — |
| 2005 No. 58 | 8 Apr 2005 (*see* F2005L00702) | 11 Apr 2005 | — |
| 2005 No. 59 | 8 Apr 2005 (*see* F2005L00707) | 11 Apr 2005 | — |
| 2005 No. 60 | 8 Apr 2005 (*see* F2005L00701) | 11 Apr 2005 | — |
| 2005 No. 61 | 8 Apr 2005 (*see* F2005L00706) | 11 Apr 2005 | — |
| 2005 No. 62 | 8 Apr 2005 (*see* F2005L00850) | 11 Apr 2005 | — |
| 2005 No. 85 | 26 May 2005 (*see* F2005L01201) | 5 June 2005 | — |
| 2005 No. 86 | 26 May 2005 (*see* F2005L01202) | 5 June 2005 | — |
| 2005 No. 87 | 26 May 2005 (*see* F2005L01203) | 5 June 2005 | — |
| 2005 No. 88 | 26 May 2005 (*see* F2005L01204) | 5 June 2005 | — |
| 2005 No. 214 | 6 Oct 2005 (*see* F2005L02976) | 7 Oct 2005 | — |
| 2005 No. 298 | 16 Dec 2005 (*see* F2005L04036) | 17 Dec 2005 | — |
| 2006 No. 178 | 14 July 2006 (*see* F2006L01551) | 15 July 2006 | — |
| 2006 No. 220 | 25 Aug 2006 (*see* F2006L02639) | 26 Aug 2006 | — |
| 2006 No. 221 | 25 Aug 2006 (*see* F2006L02640) | 26 Aug 2006 | — |
| 2006 No. 276 | 2 Nov 2006 (*see* F2006L03473) | 3 Nov 2006 | — |
| 2006 No. 277 | 2 Nov 2006 (*see* F2006L03474) | 3 Nov 2006 | — |
| 2006 No. 278 | 2 Nov 2006 (*see* F2006L03475) | 3 Nov 2006 | — |
| 2006 No. 279 | 2 Nov 2006 (*see* F2006L03476) | 3 Nov 2006 | — |
| 2006 No. 280 | 2 Nov 2006 (*see* F2006L03538) | 3 Nov 2006 | — |
| 2007 No. 3 | 16 Feb 2007 (*see* F2007L00284) | 17 Feb 2007 | — |
| 2007 No. 39 | 23 Mar 2007 (*see* F2007L00577) | 24 Mar 2007 | — |
| 2007 No. 47 | 30 Mar 2007 (*see* F2007L00847) | 31 Mar 2007 | — |
| 2007 No. 48 | 30 Mar 2007 (*see* F2007L00850) | 31 Mar 2007 | — |
| 2007 No. 49 | 30 Mar 2007 (*see* F2007L00713) | 31 Mar 2007 | — |
| 2007 No. 50 | 30 Mar 2007 (*see* F2007L00851) | 31 Mar 2007 | — |
| 2007 No. 51 | 30 Mar 2007 (*see* F2007L00848) | 31 Mar 2007 | — |
| 2007 No. 52 | 30 Mar 2007 (*see* F2007L00712) | 31 Mar 2007 | — |
| 2007 No. 125 | 24 May 2007 (*see* F2007L01465) | 25 May 2007 | — |
| 2007 No. 265 | 7 Sept 2007 (*see* F2007L03535) | 8 Sept 2007 | — |
| 2007 No. 266 | 7 Sept 2007 (*see* F2007L03537) | 8 Sept 2007 | — |
| 2007 No. 267 | 7 Sept 2007 (*see* F2007L03536) | 8 Sept 2007 | — |
| 2007 No. 290 | 27 Sept 2007 (*see* F2007L03752) | 28 Sept 2007 | — |
| 2008 No. 160 | 8 Aug 2008 (*see* F2008L02843) | 9 Aug 2008 | — |
| 2008 No. 161 | 8 Aug 2008 (*see* F2008L02845) | 9 Aug 2008 | — |
| 2008 No. 162 | 8 Aug 2008 (*see* F2008L02844) | 9 Aug 2008 | — |
| 2008 No. 218 | 31 Oct 2008 (*see* F2008L03611) | 1 Nov 2008 | — |
| 2008 No. 219 | 31 Oct 2008 (*see* F2008L03612) | 1 Nov 2008 | — |
| 2008 No. 220 | 31 Oct 2008 (*see* F2008L03610) | 1 Nov 2008 | — |
| 2009 No. 34 | 13 Mar 2009 (*see* F2009L00835) | 14 Mar 2009 | — |
| 2009 No. 35 | 13 Mar 2009 (*see* F2009L00834) | 14 Mar 2009 | — |
| 2009 No. 36 | 13 Mar 2009 (*see* F2009L00838) | 14 Mar 2009 | — |
| 2009 No. 37 | 13 Mar 2009 (*see* F2009L00837) | 14 Mar 2009 | — |
| 2009 No. 38 | 13 Mar 2009 (*see* F2009L00836) | 14 Mar 2009 | — |
| 2009 No. 39 | 13 Mar 2009 (*see* F2009L00833) | 14 Mar 2009 | — |
| 2009 No. 77 | 15 May 2009 (*see* F2009L01297) | 16 May 2009 | — |
| 2009 No. 124 | 25 June 2009 (*see* F2009L02476) | *(b)* | — |
| 2009 No. 125 | 25 June 2009 (*see* F2009L02471) | *(b)* | — |
| 2009 No. 126 | 25 June 2009 (*see* F2009L02477) | *(b)* | — |
| 2009 No. 127 | 25 June 2009 (*see* F2009L02478) | *(b)* | — |
| 2009 No. 208 | 21 Aug 2009 (*see* F2009L03208) | 22 Aug 2009 | — |
| 2009 No. 212 | 7 Sept 2009 (*see* F2009L03396) | 8 Sept 2009 | — |
| 2009 No. 213 | 7 Sept 2009 (*see* F2009L03397) | 8 Sept 2009 | — |
| 2009 No. 214 | 7 Sept 2009 (*see* F2009L03398) | 8 Sept 2009 | — |
| 2009 No. 215 | 7 Sept 2009 (*see* F2009L03399) | 8 Sept 2009 | — |
| 2010 No. 219 | 21 July 2010 (*see* F2010L02093) | 22 July 2010 | — |
| 2010 No. 220 | 21 July 2010 (*see* F2010L02094) | 22 July 2010 | — |
| 2010 No. 221 | 21 July 2010 (*see* F2010L02095) | 22 July 2010 | — |
| 2010 No. 222 | 21 July 2010 (*see* F2010L02096) | *(c)* | — |
| 2010 No. 252 | 28 Oct 2010 (*see* F2010L02825) | 29 Oct 2010 | — |
| 2010 No. 253 | 28 Oct 2010 (*see* F2010L02826) | 29 Oct 2010 | — |
| 2010 No. 254 | 28 Oct 2010 (*see* F2010L02828) | 29 Oct 2010 | — |
| 2011 No. 45 | 8 Apr 2011 (*see* F2011L00586) | 9 Apr 2011 | — |
| 2012 No. 22 | 9 Mar 2012 (*see* F2012L00553) | 10 Mar 2012 | — |
| 2012 No. 23 | 9 Mar 2012 (*see* F2012L00554) | 10 Mar 2012 | — |
| 2012 No. 24 | 9 Mar 2012 (*see* F2012L00555) | 10 Mar 2012 | — |
| 2012 No. 25 | 9 Mar 2012 (*see* F2012L00556) | 10 Mar 2012 | — |
| 2012 No. 40 | 5 Apr 2012 (*see* F2012L00796) | 9 Apr 2012 | — |
| 2012 No. 59 | 11 May 2012 (*see* F2012L01016) | 12 May 2012 | — |
| 2012 No. 191 | 17 Aug 2012 (*see* F2012L01693) | 18 Aug 2012 | — |
| 2012 No. 192 | 17 Aug 2012 (*see* F2012L01694) | 18 Aug 2012 | — |
| 2012 No. 193 | 17 Aug 2012 (*see* F2012L01695) | 18 Aug 2012 | — |
| 2012 No. 194 | 17 Aug 2012 (*see* F2012L01696) | 18 Aug 2012 | — |
| 2012 No. 195 | 17 Aug 2012 (*see* F2012L01697) | 18 Aug 2012 | — |
| 66, 2013 | 23 May 2013 (*see* F2013L00825) | 28 May 2013 (*see* s.2) | — |
| 160, 2013 | 11 July 2013 (*see* F2013L01353) | 12 July 2013 | — |
| 161, 2013 | 11 July 2013 (*see* F2013L01357) | 12 July 2013 | — |
| 162, 2013 | 11 July 2013 (*see* F2013L01358) | 12 July 2013 | — |
| 163, 2013 | 11 July 2013 (*see* F2013L01354) | 12 July 2013 | — |
| 164, 2013 | 11 July 2013 (*see* F2013L01356) | 12 July 2013 | — |
| 165, 2013 | 11 July 2013 (*see* F2013L01355) | 12 July 2013 | — |
| 241, 2013 | 25 Nov 2013 (*see* F2013L01969) | 26 Nov 2013 | — |
| 47, 2014 | 16 May 2014 (*see* F2014L00550) | 17 May 2014 | — |
| 117, 2014 | 5 Aug 2014 (F2014L01073) | 6 Aug 2014 (s 2) | — |

*(a)* Schedule 1 (item 3) of the *Criminal Code Amendment (Terrorist Organisations) Act 2002* provides as follows:

**3 Effect of regulations made before commencement of this Act**

In spite of anything in subsection 102.1(4) of the *Criminal Code* before it was repealed, or in the regulations concerned, regulations made for the purposes of paragraph (c) of the definition of ***terrorist organisation*** in section 102.1 of the *Criminal Code* that were notified in the *Gazette* before the commencement of this Act are deemed to have taken effect on 21 October 2002. Section 48 of the *Acts Interpretation Act 1901* has effect subject to this item.

*(b)* The repeal by the *Criminal Code (Repeal of Amendments) Regulations 2009* (SLI 2009 No. 176) of the *Criminal Code Amendment Regulations 2009 (No. 8)* (SLI 2009 No. 124), the *Criminal Code Amendment Regulations 2009 (No. 9)* (SLI 2009 No. 125), the *Criminal Code Amendment Regulations 2009 (No. 10)* (SLI 2009 No. 126) and the *Criminal Code Amendment Regulations 2009 (No. 11)* (SLI 2009 No. 127) takes effect before these instruments commenced, the amendments made by the instruments are taken never to have come into effect.

*(c)* Regulation 2 of the *Criminal Code Amendment Regulations 2010 (No. 4)* provides as follows:

These Regulations commence on the first day on which they are no longer liable to be disallowed, or to have been taken to have been disallowed, under section 42 of the *Legislative Instruments Act 2003*.

Note: The disallowance period provided for by section 42 of the *Legislative Instruments Act 2003* may be extended if a report on a review of these Regulations by the Parliamentary Joint Committee on ASIO, ASIS and DSD is tabled within 15 sittings days after the Regulations are tabled—see subsection 102.1A(3) of the *Criminal Code Act 1995*.

The *Criminal Code Amendment Regulations 2010 (No. 4)* (SLI 2010 No. 222) commenced on 27 November 2010.

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| Heading to Part 1 | ad. 2002 No. 248 |
| r. 3 | am. 2007 No. 265 |
| **Part 2** |  |
| Part 2 | ad. 2002 No. 248 |
| Heading to r. 4 | rep. 2005 No. 298 |
| r. 4 | ad. 2002 No. 248 |
|  | rs. 2003 No. 184 |
|  | am. 2003 No. 285; 2005 Nos. 85, 86, 87 and 88 |
|  | rep. 2005 No. 298 |
|  | ad. 2006 No. 178 |
|  | am. 2006 No. 280 |
| Note to r. 4 | am. 2003 No. 285 |
|  | rep. 2005 No. 298 |
| r. 4A | ad. 2004 No. 283 |
|  | rs. 2006 No. 220, 2008 No. 160; 2010 No. 219 |
|  | rep. No. 161, 2013 |
| r. 4B | ad. 2004 No. 284 |
|  | rs. 2006 No. 221; 2008 No. 161; 2010 No. 220 |
|  | rep. No. 165, 2013 |
| r. 4C | ad. 2004 No. 311 |
|  | rs. 2006 No. 276; 2008 No. 218; 2010 No. 253 |
|  | rep. No. 160, 2013 |
| r. 4D | ad. 2004 No. 312 |
|  | rs. 2006 No. 277; 2008 No. 220; 2010 No. 252 |
|  | rep. No. 164, 2013 |
| r. 4E | ad. 2004 No. 313 |
|  | rs. 2006 No. 278 |
|  | rep. 2012 No. 191 |
| r. 4F | ad. 2004 No. 314 |
|  | rs. 2006 No. 279; 2008 No. 162; 2010 No. 221 |
|  | rep. No. 163, 2013 |
| r. 4G | ad. 2005 No. 23 |
|  | rs. 2007 No. 3; 2008 No. 219; 2010 No. 254 |
|  | rep. No. 162, 2013 |
| r. 4H | ad. 2005 No. 36 |
|  | rs. 2007 No. 39; 2009 No. 34; 2012 No. 22 |
| r. 4I | ad. 2005 No. 60 |
|  | rs. 2007 No. 47; 2009 No. 35 |
|  | rep. 2012 No. 191 |
| r. 4J | ad. 2005 No. 58 |
|  | rs. 2007 No. 48; 2009 No. 39; 2012 No. 23 |
| r. 4K | ad. 2005 No. 57 |
|  | rs. 2007 No. 52; 2009 No. 36; 2012 No. 24 |
| r. 4L | ad. 2005 No. 61 |
|  | rs. 2007 No. 49; 2009 No. 38; 2012 No. 25 |
| r. 4M | ad. 2005 No. 59 |
|  | rs. 2007 No. 50 |
|  | rep. 2012 No. 191 |
| r. 4N | ad. 2005 No. 62 |
|  | rs. 2007 No. 51; 2009 No. 37 |
|  | rep. 2012 No. 191 |
| r. 4P | ad. 2005 No. 88 |
|  | rep. 2005 No. 214 |
| r. 4Q | ad. 2005 No. 85 |
|  | rs. 2007 No. 125; 2009 No. 77; 2012 No. 59 |
| r. 4R | ad. 2005 No. 86 |
|  | rep. 2005 No. 214 |
| r. 4S | ad. 2005 No. 87 |
|  | rep. 2005 No. 214 |
| r. 4T | ad. 2005 No. 214 |
|  | rs. 2007 No. 265; 2009 No. 212; 2012 No. 194 |
| r. 4U | ad. 2005 No. 214 |
|  | rs. 2007 No. 266; 2009 No. 213; 2012 No. 191 |
| r. 4V | ad. 2005 No. 214 |
|  | rs. 2007 No. 267; 2009 No. 214; 2012 No. 192 |
| r. 4W | ad. 2005 No. 298 |
|  | rs. 2007 No. 290; 2009 No. 215; 2012 No. 195 |
| r. 4X | ad. 2009 No. 208 |
|  | rs. 2012 No. 193 |
| r. 4Y | ad. 2010 No. 222 |
|  | rep No 241, 2013 |
| **Part 3** |  |
| Heading to Part 3 | rs. No. 66, 2013 |
| **Division 3.1** |  |
| Heading to Div. 3.1  of Part 3 | ad. No. 66, 2013 |
| Part 3 | ad. 2003 No. 30 |
| r. 5AA | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| r. 5AB | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| r. 5AC | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| r. 5 | ad. 2003 No. 30 |
| **Division 3.2** |  |
| Div. 3.2 of Part 3 | ad. No. 66, 2013 |
| r. 5A | ad. No. 66, 2013 |
| r. 5B | ad. No. 66, 2013 |
| r. 5C | ad. No. 66, 2013 |
| r. 5D | ad. No. 66, 2013 |
| r. 5E | ad. No. 66, 2013 |
| r. 5F | ad. No. 66, 2013 |
| **Part 4** |  |
| Heading to Part 3 | ad. 2002 No. 248 |
| Renumbered as Part 4 | 2003 No. 30 |
| r. 4 |  |
| Renumbered as r. 5 | 2002 No. 248 |
| r. 5 |  |
| Renumbered as r. 6 | 2003 No. 30 |
| **Schedule 1** |  |
| Schedule 1 | ad. 2002 No. 248 |
|  | am. 2002 Nos. 249, 250, 269, 270, 271 and 272; 2003 Nos. 43, 59, 60, 61, 62, 63 and 64; 2004 Nos. 83, 283, 284, 311, 312, 313 and 314; 2005 Nos. 36, 57, 58, 59, 60, 61 and 62 |
|  | rep. 2005 No. 88 |
|  | ad. 2006 No. 178 |
|  | am. 2006 No. 280 |
| Heading to Schedule 1A | rs. 2003 No. 285 |
|  | rep. 2005 No. 298 |
|  | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| Schedule 1A | ad. 2003 No. 184 |
|  | rep. 2005 No. 298 |
|  | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| Heading to Part 1 | ad. 2003 No. 285 |
|  | rep. 2005 No. 85 |
|  | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| Part 1 | rep. 2005 No. 85 |
|  | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| Part 2 | ad. 2003 No. 285 |
|  | rep. 2005 No. 86 |
|  | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| Part 3 | ad. 2003 No. 285 |
|  | rep. 2005 No. 87 |
|  | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| Part 4 | ad. 2011 No. 45 |
|  | rep. 2012 No. 40 |
| **Schedule 2** |  |
| Schedule 2 | ad. 2003 No. 30 |
| **Schedule 3** |  |
| Schedule 3 | ad. No. 66, 2013 |
|  | am No 62, 2014 |
| **Schedule 4** |  |
| Schedule 4 | ad. No. 66, 2013 |
|  | am No 47, 2014 |

Endnote 5—Uncommenced amendments [none]

Endnote 6—Modifications [none]

Endnote 7—Misdescribed amendments [none]

Endnote 8—Miscellaneous [none]